Похідні [(N-арил)піперазиніл]бутилпіримідинів, які володіють нейротропними та актопротекторними властивостями
In this study the potential ligands of 5-HT1A receptors – arylpiperazines containing the residues of tetrahydropyrimidine as terminal fragments, compounds (1-6) and dihydropyrimidine – (7) have been synthesized. The structures of compounds 1-7 have been confi rmed by IR-spectroscopy, mass spectrometr...
Збережено в:
| Дата: | 2016 |
|---|---|
| Автори: | , , , , , |
| Формат: | Стаття |
| Мова: | Russian |
| Опубліковано: |
National University of Pharmacy
2016
|
| Теми: | |
| Онлайн доступ: | https://ophcj.nuph.edu.ua/article/view/ophcj.16.875 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Journal of Organic and Pharmaceutical Chemistry |
Репозитарії
Journal of Organic and Pharmaceutical Chemistry| Резюме: | In this study the potential ligands of 5-HT1A receptors – arylpiperazines containing the residues of tetrahydropyrimidine as terminal fragments, compounds (1-6) and dihydropyrimidine – (7) have been synthesized. The structures of compounds 1-7 have been confi rmed by IR-spectroscopy, mass spectrometry and 1H-NMR-spectroscopy. Substances 2, 3, 4 and 7 inhibit the specifi c binding of the radioligand [3H]8-OH-DPAT with 5-HT1A receptors; it has been found that they have a pronounced affi nity for these receptors. In the confl ict situation test compounds of 1-5 and 7 showed anxiolytic properties, whereas phenylpiperazinil- and о-tolylpiperazinilbutyl-4-methyl-5-izopropyl-1,2,3,-6-tetrahydropyrimidine-2-thio-6-ones (1 and 2) exceeded the known drug buspirone by the level of the anxiolytic activity. The absence of this activity in compound 6 is probably due to the differences of substituents at N1 atom of the pyrimidine nucleus of compound 6 and other compounds of this series. It has been shown that on the model of hyperthermia all of these compounds in the dose range of 0.04-0.1 mg/kg possessed a high actoprotective activity increased the rat capacity work by 1.4-2.5 times compared to the control. The most active compound 3 in the ED50 dose of 0.04 mg/kg increased the duration of swimming in rats by 2.2 times (122%) compared to bemithylum. Some of the compounds (15 mg/kg) showed antihypoxic activity on the models of hemic (compounds 2-4, 7) and normobaric hypoxia (compounds 1, 2, 6) and exceeded bemithylym (33.5 mg/kg) by their activity. The compounds synthesized are low toxic with the LD50 value of 150-250 mg/kg. |
|---|